Dianthus Therapeutics DNTH Accrued Expenses
Accrued Expenses at other companies
Other financials
Where this comes from
Reported directly by Dianthus Therapeutics in its filing.
Tagged under the XBRL concept us-gaap:AccruedLiabilitiesCurrent.
The official record: Dianthus Therapeutics’s 10-Q, filed May 5, 2026, on SEC EDGAR. View the filing →
Ask your AI about Dianthus Therapeutics's accrued expenses.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Dianthus Therapeutics's accrued expenses?
- Dianthus Therapeutics (DNTH) reported accrued expenses of $31.13M in Q1 2026.
- How has Dianthus Therapeutics's accrued expenses changed year-over-year?
- Dianthus Therapeutics's accrued expenses increased by 290.1% year-over-year, from $7.98M to $31.13M.
- What is the long-term trend for Dianthus Therapeutics's accrued expenses?
- Over 5 years (2020 to 2025), Dianthus Therapeutics's accrued expenses has grown at a 20.5% compound annual growth rate (CAGR), from $7.67M to $19.45M.
- What does accrued expenses mean?
- Expenses incurred but not yet paid or invoiced — interest accruals, tax accruals, warranty reserves, and other timing differences.